Neuragen® gel versus placebo in the relief of neuropathic foot pain

The effectiveness of Neuragen® gel versus placebo in the relief of neuropathic foot pain: a double-blind randomised placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN37736407

Enrollment

Registered

2009-11-09

Start date

2009-11-09

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral neuropathy Nervous System Diseases Other polyneuropathies

Interventions

This is a double blind randomised clinical trial. The company pre-packages the treatments in two identical containers labeled A and B

each contains one application of the topical Neuragen® gel and placebo. A or B will be applied to the foot sole of the participants only once each, at least seven days apart between the two applicatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female aged over 21 years 2. Diagnosed with neuropathic pain more 3 months 3. Pain level between 5 - 9 on a 0 - 10 visual pain scale 4. Does not have mental and communication impairments

Exclusion criteria

Exclusion criteria: 1. Pregnant 2. Have other types of pain 3. Skin condition 4. Central nerve impairments

Design outcomes

Primary

Measure	Time frame
Level of pain on a 0 - 10 visual pain scale, measured 30 minutes before and after the application of of the treatment, and every hour thereafter for 8 hours.	—

Secondary

Measure	Time frame
Duration of pain reduction, measured on a 0 - 10 visual pain scale which will be used every hour on the hour for up to 8 hours.	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026